Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men

British Journal of Clinical Pharmacology

Volumn 74, Issue 6, 2012, Pages 999-1004

  Qin, Wen Jie ^a,b   Zhang, Wei ^a   Liu, Zhao Qian ^a   Chen, Xiao Ping ^a   Tan, Zhi Rong ^a   Hu, Dong Li ^a   Wang, Dan ^a   Fan, Lan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Province Geriatric Hospital   (China)

Author keywords

Bupropion; CYP2B6; Genotype; Hydroxybupropoion; Induction; Metamizole

Indexed keywords

4 HYDROXYBUPROPION; AMFEBUTAMONE; CYTOCHROME P450 2B6; DIPYRONE; RADAFAXINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BUPROPION; DIPYRONE; DRUG INTERACTIONS; GENOTYPE; HUMANS; HYDROXYLATION; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; YOUNG ADULT;

EID: 84869054463     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04304.x     Document Type: Article

References (21)

1. Ramacciotti AS, Soares BG, Atallah AN. Dipyrone for acute primary headaches. Cochrane Database Syst Rev 2007; (2): CD004842.
2. Maj S, Centkowski P. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Med Sci Monit 2004; 10: PI93-PI95.
3. Arellano F, Sacristán JA. Metamizole: reassessment of its therapeutic role. Eur J Clin Pharmacol 1990; 38: 617-9.
4. Caraco Y, Zylber-Katz E, Fridlander M, Admon D, Levy M. The effect of short-term dipyrone administration on cyclosporine pharmacokinetics. Eur J Clin Pharmacol 1999; 55: 475-8.
5. Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 2007; 82: 265-74.
6. Kraul H, Pasanen M, Sigusch H, Stenbäck F, Park SS, Gelboin HV, Pelkonen O. Immunohistochemical properties of dipyrone-induced cytochromes P450 in rats. Hum Exp Toxicol 1996; 15: 45-50.
7. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006; 80: 75-84.
8. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49: 513-9.
9. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52: 1663-9.
10. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D, Zhou HH. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 2009; 65: 403-9.
11. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003; 74: 326-33.
12. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77: 553-9.
13. Farid NA, Payne CD, Ernest CS 2nd, Li YG, Winters KJ, Salazar DE, Small DS. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol 2008; 48: 53-9.
14. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007; 62: 635-41.
15. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-9.
16. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005; 27: 1685-95.
17. Johnston JA, Fiedler-Kelly J, Glover ED etal. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3: 131-40.
18. Johnston AJ, Ascher J, Leadbetter R etal. Pharmacokinetic optimization of sustained-release bupropion for smoking cessation. Drugs 2002; 62: 11-24.
19. Haynes K, Faucette SR, Lindley CM, LeCluyse E, Shord S, Hawke R. Evaluation of bupropion hydroxylation as a probe of cytochrome P450 2B6 activity in cultured human hepatocytes. Paper presented at: American College of Clinical Pharmacy; October 20-23, 2002; Savannah, GA. Abstract 165.
20. Zhou J, Zhang J, Xie W. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab 2005; 6: 289-98.
21. Chung JY, Cho J-Y, Lim H-S, Kim J-R, Yu K-S, Lim KS, Shin S-G, Jang I-J. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 2011; 39: 92-7.